PKI PerkinElmer Inc.

PerkinElmer Elects Samuel Chapin to Board of Directors

PerkinElmer, Inc., (NYSE:PKI) a global leader committed to innovating for a healthier world, today announced that Samuel R. Chapin has been elected to the Company’s Board of Directors.

"I am pleased to welcome Samuel to our Board, as he brings extensive experience in strategic advisory, mergers and acquisitions, and deal financing for a wide range of transactions, along with deep knowledge of the industrial marketplace,” said Robert Friel, Chairman and Chief Executive Officer, PerkinElmer.

Chapin most recently served as Executive Vice Chairman of Global Corporate & Investment Banking for Bank of America Merrill Lynch, where he held the role since 2010 and was responsible for managing relationships with the firm's largest clients. He retired as of June 30, 2016.

Chapin was named Vice Chairman of Merrill Lynch & Co in September 2003 and was a member of the firm's executive Operating Committee. From 2001 to 2003, he was Senior Vice President and Head of the Global Investment Banking division. He previously led the investment banking group that covered industrial companies, actively managing the firm's relationships with clients in the industrial, resources and consumer products industries. He joined Merrill Lynch in 1984 as a member of the Mergers & Acquisitions group and was named a managing director in Corporate Banking in 1993. He has worked on a wide range of financings and strategic advisory assignments totaling over $500 billion. Chapin has also been named Investment Banker of the year by Investment Dealers' Digest.

Chapin received a Bachelor of Arts from Lafayette College and a Master of Business Administration, with distinction, from The Wharton School at the University of Pennsylvania. He also serves on the board of trustees at Lafayette College and is a director for the Wharton Financial Advisory Board. Chapin is also a member of the board of directors of the Roundabout Theatre Company.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. The Company reported revenue of approximately $2.3 billion in 2015, has approximately 8,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE or at www.perkinelmer.com.

EN
17/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PerkinElmer Inc.

Revvity, Inc. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Revvity, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 24 June 2025 in which we reassessed the appropriateness of the ratings in the context of the ...

 PRESS RELEASE

Revvity’s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with N...

WALTHAM, Mass.--(BUSINESS WIRE)-- (NYSE: RVTY), announced today that its business has launched the (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics. Now available in countries accepting the CE mark, this all-in-one solution increases the efficiency of the entire IIFT process, encompassing sample preparation, incubation, washing and mounting of slides as well as image acquisition and analysis. “Traditional IIFT processing can be tedious and time-consuming, requiring the expertise of specially trained lab technicians and a dark room,”...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch